Eli Lilly and Co (LLY) : Ntv Asset Management reduced its stake in Eli Lilly and Co by 0.69% during the most recent quarter end. The investment management company now holds a total of 60,256 shares of Eli Lilly and Co which is valued at $4,495,098 after selling 417 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on May 2, 2016.Eli Lilly and Co makes up approximately 1.72% of Ntv Asset Management’s portfolio.
Eli Lilly and Co closed down -0.67 points or -0.89% at $74.6 with 41,96,917 shares getting traded on Friday. Post opening the session at $74.715, the shares hit an intraday low of $73.34 and an intraday high of $74.95 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Atwood Palmer Inc reduced its stake in LLY by selling 600 shares or 53.67% in the most recent quarter. The Hedge Fund company now holds 518 shares of LLY which is valued at $39,125. Eli Lilly and Co makes up approx 0.01% of Atwood Palmer Inc’s portfolio.Wilbanks Smith Thomas Asset Management reduced its stake in LLY by selling 322 shares or 6.2% in the most recent quarter. The Hedge Fund company now holds 4,873 shares of LLY which is valued at $368,058. Eli Lilly and Co makes up approx 0.04% of Wilbanks Smith Thomas Asset Management’s portfolio.Gateway Investment Advisers reduced its stake in LLY by selling 18,429 shares or 2.38% in the most recent quarter. The Hedge Fund company now holds 757,462 shares of LLY which is valued at $58,953,267. Eli Lilly and Co makes up approx 0.50% of Gateway Investment Advisers’s portfolio.Bennicas Associates reduced its stake in LLY by selling 1,900 shares or 8.41% in the most recent quarter. The Hedge Fund company now holds 20,700 shares of LLY which is valued at $1,611,081. Eli Lilly and Co makes up approx 1.50% of Bennicas Associates’s portfolio.
On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.